New vaccine support (NVS) for PENTA
GAVI’s support for new vaccines presents an opportunity for countries to not only implement vaccines that protect against diseases causing substantial morbidity and/or mortality, but also to build upon the vaccine investments in order to increase immunisation coverage rates, and strengthen routine immunisation services and primary health care systems. The pentavalent vaccine, administered in a three-dose schedule, offers protection against five diseases: diphtheria-tetanus-pertussis (DTP), heptatitis B and Haemophilius influenzae type b. Until 2013, GAVI has helped to introduce the pentavalent in 70 of the 73 GAVI-eligible countries, with the aim of reaching all 73 by the end of 2014. GAVI support for pentavalent vaccine is in line with WHO recommendations, for routine infant immunisation and primarily targeting children under one year of age.
- ID Projet
47122-0715-UGA-04B-X- Statut de l'activité
- 3 - Completion
- Type d'aide
- B02 - Contributions aux budgets réguliers des institutions multilatérales
- % to Ouganda
- 100.00
Organisations
- Funding
- The Global Alliance for Vaccination and Immunisation
- Extending
- World Health Organisation - core voluntary contributions account (for technical assitance)
- Accountable
- Federal States & Local Governments
- Implementing
- Federal States & Local Governments
- Extending
- United Nations Childrens Fund
Versements par exercice fiscal, trimestre
| Exercice fiscal |
Trimestre fiscal |
Montant (USD) |
Ouganda Montant (USD) |
| 2013 |
Q2 |
-353,492.00 |
-353,492.00 |
| 2012 |
Q2 |
-15,192.00 |
-15,192.00 |
| 2012 |
Q1 |
6,222,657.00 |
6,222,657.00 |
| 2011 |
Q3 |
2,084,941.00 |
2,084,941.00 |
| 2011 |
Q2 |
4,512,945.00 |
4,512,945.00 |
| 2011 |
Q1 |
3,100,606.00 |
3,100,606.00 |
| 2010 |
Q4 |
4,652,398.00 |
4,652,398.00 |
| 2010 |
Q3 |
274,662.00 |
274,662.00 |
| 2010 |
Q1 |
-61,188.00 |
-61,188.00 |
| 2009 |
Q4 |
4,786,679.00 |
4,786,679.00 |
| 2009 |
Q3 |
3,237,383.00 |
3,237,383.00 |
| 2009 |
Q2 |
1,461,345.00 |
1,461,345.00 |
| 2009 |
Q1 |
2,191,042.00 |
2,191,042.00 |
| 2008 |
Q4 |
2,140,042.00 |
2,140,042.00 |
| 2008 |
Q3 |
2,491,578.00 |
2,491,578.00 |
| 2008 |
Q2 |
6,772,404.00 |
6,772,404.00 |
| 2008 |
Q1 |
205,000.00 |
205,000.00 |
| 2007 |
Q4 |
1,447,431.00 |
1,447,431.00 |
| 2007 |
Q3 |
8,898,585.00 |
8,898,585.00 |
| 2007 |
Q2 |
3,607,809.00 |
3,607,809.00 |
| 2006 |
Q4 |
4,696,422.00 |
4,696,422.00 |
| 2006 |
Q3 |
4,962,959.00 |
4,962,959.00 |
| 2006 |
Q2 |
4,999,756.00 |
4,999,756.00 |
Engagements par exercice fiscal, trimestre
| Exercice fiscal |
Trimestre fiscal |
Montant (USD) |
Ouganda Montant (USD) |
| 2012 |
Q2 |
-88,580.00 |
-88,580.00 |
| 2011 |
Q1 |
11,626,500.00 |
11,626,500.00 |
| 2010 |
Q4 |
-663,500.00 |
-663,500.00 |
| 2010 |
Q2 |
-167,791.00 |
-167,791.00 |
| 2010 |
Q1 |
8,151,500.00 |
8,151,500.00 |
| 2009 |
Q2 |
-3,776,609.00 |
-3,776,609.00 |
| 2008 |
Q2 |
11,906,500.00 |
11,906,500.00 |
| 2007 |
Q2 |
22,186,250.00 |
22,186,250.00 |
| 2007 |
Q1 |
-914,613.00 |
-914,613.00 |
| 2006 |
Q1 |
22,616,500.00 |
22,616,500.00 |
Projections de CDMT par exercice fiscal
| Exercice fiscal |
Montant (USD) |
Ouganda Montant (USD) |
| 2015 |
3,132,500.00 |
3,132,500.00 |
| 2014 |
6,983,250.00 |
6,983,250.00 |
| 2013 |
8,577,500.00 |
8,577,500.00 |
| 2012 |
9,880,500.00 |
9,880,500.00 |
| 2011 |
10,465,250.00 |
10,465,250.00 |
| 2010 |
11,618,000.00 |
11,618,000.00 |
| 2009 |
13,179,500.00 |
13,179,500.00 |
| 2008 |
14,560,500.00 |
14,560,500.00 |
| 2007 |
15,152,000.00 |
15,152,000.00 |
| 2006 |
7,464,500.00 |
7,464,500.00 |
| Code CRS |
% |
|
Lutte contre les maladies infectieuses
(12250)
|
100.0
|